01
Overview
OT4B is conducting a Phase III clinical trial called OTBB3 for oxytocin treatment in Prader-Willi syndrome. The company is developing oxytocin as the first treatment for patients with this rare disease.
- Therapeutic areas
- Rare Diseases
- Modalities
- Peptide (oxytocin)
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Toulouse University HospitalCREAPHARM
Beyond the preview
Go deeper on OT4B.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OT4B.